Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDI Calidi Biotherapeutics	$1.70 -43.3%	$5.52	$1.65 ▼ $46.68	$5.14M	1.15	649,634 shs	2.79 million shs
FNCH Finch Therapeutics Group	$12.03 -3.8%	$12.79	$10.15 ▼ $15.85	$19.32M	1.19	2,152 shs	101 shs
JATT JATT Acquisition	$1.73 -0.6%	$1.38	$7.80 ▼ $12.38	$29.84M	N/A	41,322 shs	375,465 shs
ONCE Spark Therapeutics	$0.18	$113.43	$34.53 ▼ $114.20	$6.94M	2.05	891,560 shs	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDI Calidi Biotherapeutics	-26.83%	-43.29%	-57.88%	-38.30%	-83.77%
FNCH Finch Therapeutics Group	-1.57%	+2.04%	0.00%	-8.09%	+11.01%
JATT JATT Acquisition	+4.82%	+23.40%	-8.90%	+62.62%	-50.00%
ONCE Spark Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDI Calidi Biotherapeutics	0.8199 of 5 stars	0.0	4.0	0.0	0.0	2.5	0.0	0.6
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCE Spark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDI Calidi Biotherapeutics	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A
ONCE Spark Therapeutics	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	($2.32) per share	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
JATT JATT Acquisition	N/A	N/A	$0.06 per share	27.08	($0.53) per share	N/A
ONCE Spark Therapeutics	$64.72M	0.11	N/A	N/A	$13.15 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDI Calidi Biotherapeutics	-$29.22M	N/A	0.00	N/A	N/A	N/A	N/A	-344.45%	N/A
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A
JATT JATT Acquisition	$6.85M	N/A	0.00	∞	N/A	N/A	-49.58%	2.84%	N/A
ONCE Spark Therapeutics	-$78.82M	-$2.11	N/A	N/A	N/A	-358.41%	-59.10%	-33.13%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A
ONCE Spark Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDI Calidi Biotherapeutics	N/A	0.19	0.19
FNCH Finch Therapeutics Group	N/A	3.87	3.87
JATT JATT Acquisition	N/A	0.15	0.15
ONCE Spark Therapeutics	0.35	4.67	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDI Calidi Biotherapeutics	12.53%
FNCH Finch Therapeutics Group	21.77%
JATT JATT Acquisition	47.97%
ONCE Spark Therapeutics	88.37%

Insider Ownership

Company	Insider Ownership
CLDI Calidi Biotherapeutics	6.70%
FNCH Finch Therapeutics Group	44.90%
JATT JATT Acquisition	20.00%
ONCE Spark Therapeutics	6.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDI Calidi Biotherapeutics	38	3.03 million	20.04 million	N/A
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
JATT JATT Acquisition	3	17.25 million	13.80 million	Not Optionable
ONCE Spark Therapeutics	368	38.52 million	N/A	No Data

ONCE, JATT, FNCH, and CLDI Headlines

Recent News About These Companies

Spark layoffs won’t derail Philadelphia’s biotech surge, city official says

May 10, 2025 | technical.lyT

How Spark's layoffs could affect University City real estate

April 11, 2025 | bizjournals.com

Despite Spark's massive layoffs, co-founder Jeff Marrazzo says its legacy will endure

April 9, 2025 | bizjournals.com

Spark Therapeutics files notice to lay off 300 employees this year

April 5, 2025 | technical.lyT

Spark Therapeutics Cuts 298 Employees as Part of Reorganization

April 4, 2025 | biospace.comB

Spark Therapeutics is laying off 337 people, more than half its workforce, starting in May

April 3, 2025 | msn.com

Does the Spark Therapeutics writedown undermine Philly’s biotech swagger?

March 18, 2025 | technical.lyT

Roche to buy gene therapy firm Spark for $4.8 billion

March 13, 2025 | pharmaphorum.comP

Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit

March 12, 2025 | biospace.comB

Spark Therapeutics, a Philly biotech pioneer, is being restructured amid financial write-downs

March 4, 2025 | msn.com

Pfizer shelves Beqvez, a Spark Therapeutics developed product

February 24, 2025 | bizjournals.com

Spark Therapeutics co-founder back at the helm of a Philadelphia gene therapy company

January 14, 2025 | bizjournals.com

Spark reassures on safety of haemophilia gene therapy

December 25, 2024 | pharmaphorum.comP

Roche mothballs another hemophilia A gene therapy under Spark amid plans to debut new hematologic asset

December 17, 2024 | fiercebiotech.comF

How ADHD wired me for scientific discovery

November 12, 2024 | statnews.comS

Huntington Study Group (HSG) Conference 2024 – Day 1

November 11, 2024 | en.hdbuzz.netE

Bitcoin breaks $81,000 for first time on Trump trades; UK government sells £1bn of NatWest shares – business live

November 11, 2024 | msn.com

Meet the contenders: Vote for the winners of Philly’s 2024 Technical.ly Awards

November 7, 2024 | technical.lyT

Denver police investigate deadly hit-and-run at South Sheridan and Evans Avenue

November 6, 2024 | yahoo.com

Trump trades: US dollar, stock futures, bonds, Bitcoin

November 6, 2024 | sharecafe.com.auS

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ONCE, JATT, FNCH, and CLDI Company Descriptions

Calidi Biotherapeutics NYSE:CLDI

$1.70 -1.30 (-43.33%)

Closing price 03:59 PM Eastern

Extended Trading

$1.72 +0.02 (+0.88%)

As of 04:11 PM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Finch Therapeutics Group NASDAQ:FNCH

$12.03 -0.47 (-3.76%)

As of 03:38 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

JATT Acquisition NYSE:JATT

$1.73 -0.01 (-0.57%)

As of 08/19/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Spark Therapeutics NASDAQ:ONCE

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time